EICHORPublic-registry site landscape for NCT03733691, “Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients”, a Newly Diagnosed Multiple Myeloma study sponsored by Oncotherapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03733691 (registry record) |
| Study title | Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients |
| Official title | A Phase 2, Open Label, Randomized Trial Evaluating Ixazomib Compared to Ixazomib-Lenalidomide Combination Maintenance Therapy for Frontline Multiple Myeloma Patients |
| Sponsor | Oncotherapeutics |
| Condition(s) | Newly Diagnosed Multiple Myeloma |
| Phase | PHASE2 |
| Listed sites | 1 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03733691.
Eichor generates a preliminary site-risk snapshot for NCT03733691 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
← Eichor home · All tracked trials · Newly Diagnosed Multiple Myeloma studies · Weekly briefs
